Quarterly report [Sections 13 or 15(d)]

Condensed Consolidated Statement of Stockholders' Equity (Unaudited)

v3.25.1
Condensed Consolidated Statement of Stockholders' Equity (Unaudited) - USD ($)
$ in Thousands
Total
Common Stock
Additional Paid-in Capital
Accumulated Deficit
Accumulated Other Comprehensive Loss
Beginning balance, value at Dec. 31, 2023 $ (6,905) $ 0 $ 429,780 $ (436,684) $ (1)
Beginning balance, shares at Dec. 31, 2023   4,423,683      
Issuance of common stock, net of issuance costs 108,764 $ 1 108,763    
Common stock shares issued   5,913,138      
Stock-based compensation expense 982   982    
Issuance of common stock upon exercise of stock options 226   226    
Issuance of common stock upon exercise of stock options, shares   24,231      
Issuance of common stock upon vesting of restricted stock, shares   3,328      
Change in unrealized gain (loss) on marketable debt securities (328)       (328)
Issuance of common stock upon conversion of K2 Loan and Security Agreement, Shares   142,857      
Issuance of common stock upon conversion of K2 Loan and Security Agreement, Value 1,125   1,125    
Net Income (Loss) (6,899)     (6,899)  
Ending balance, value at Mar. 31, 2024 96,965 $ 1 540,876 (443,583) (329)
Ending balance, shares at Mar. 31, 2024   10,507,237      
Beginning balance, value at Dec. 31, 2024 142,428 $ 1 619,285 (476,893) 35
Beginning balance, shares at Dec. 31, 2024   12,179,482      
Stock-based compensation expense $ 1,714   1,714    
Issuance of common stock upon exercise of stock options, shares 0        
Issuance of common stock upon vesting of restricted stock, shares   53,371      
Change in unrealized gain (loss) on marketable debt securities $ (58)       (58)
Net Income (Loss) (16,978)     (16,978)  
Ending balance, value at Mar. 31, 2025 $ 127,106 $ 1 $ 620,999 $ (493,871) $ (23)
Ending balance, shares at Mar. 31, 2025   12,232,853